More interestingly, the treatments with the novel immunomodulatory mAbs induced lower cytolysis of human cardiomyocytes co-cultured with hPBMCs, with respect to those observed with the clinically validated ipilimumab and atezolizumab, accompanied by lower levels of IL-6, a pro-inflammatory cytokine involved in the etiopathogenesis of myocarditis [32,33]. The gene discussed is IL6; the disease is myocarditis.